BlossomHill Therapeutics Q3 2026 net loss widens 50% to $24.01 million
BLSM•BlossomHill Therapeutics’ third-quarter 2026 net loss widened 50% year over year to $24.01 million, while research and development expenses rose 49% to $21.93 million. It had $224.9 million in cash and equivalents at September 30, with funding expected to last into Q2 2028.
1. Quarterly results and outlook
BlossomHill Therapeutics’ third-quarter 2026 net loss widened 50% year over year to $24.01 million, primarily due to higher operating expenses. Research and development expenses rose 49% to $21.93 million, mainly due to higher clinical development, personnel and IND-enabling costs. The company reported $224.9 million in cash and cash equivalents at September 30, 2026, and expects funding to last into Q2 2028; its pivotal SOLARA-2 trial of BH-30643 in EGFR C797S-positive lung cancer is expected to dose its first patient in Q1 2027.
